Table 2. Comparison of non-refractory and refractory MG patients.
| Total (n=128) | Non-refractory (n=109) | Refractory (n=19) | p-valueb | |
| Median age of onset, years (IQRa) | 55 (38-69) | 60 (42-72) | 36 (28-51) | <0.001 |
| Female, n (%) | 65 (51) | 51 (47)1 | 14 (74) | 0.03 |
| Antibody status available, n (%) | 115 (90) | 96 (88) | 19 (100) | |
| Anti-AChR+ | 82 (71) | 72 (75) | 10 (53) | 0.05 |
| Anti-MuSK+ | 11 (10) | 2 (2) | 9 (47) | <0.001 |
| Double Seronegative | 22 (19) | 22 (23) | 0 | 0.02 |
| Thymectomy, n (%) | 31 (24) | 18 (17) | 13 (68) | <0.001 |
| Thymoma status available, n (%) | 77 (60) | 66 (61) | 11 (58) | |
| Thymomatous | 14 (18) | 9 (14) | 5 (45) | 0.02 |
| Nonthymomatous | 63 (82) | 57 (86) | 6 (55) | |
aIQR, interquartile range; bFor comparisons of non-refractory vs. refractory